490 related articles for article (PubMed ID: 30545993)
1. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
Niraula S; Nugent Z
J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
[No Abstract] [Full Text] [Related]
2. Conditional approval of cancer drugs in Canada: accountability and impact on public funding.
Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC
Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815
[TBL] [Abstract][Full Text] [Related]
3. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.
Niraula S
Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671
[TBL] [Abstract][Full Text] [Related]
4. Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.
Parmar A; Jiao T; Saluja R; Chan KKW
Cancer Med; 2020 Jan; 9(1):94-103. PubMed ID: 31711274
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
Raymakers AJN; Regier DA; Peacock SJ
Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
[TBL] [Abstract][Full Text] [Related]
6. The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017.
Skedgel C; Wranik D; Hu M
Pharmacoeconomics; 2018 Apr; 36(4):467-475. PubMed ID: 29353385
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
Meyers DE; Jenei K; Chisamore TM; Gyawali B
JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
[TBL] [Abstract][Full Text] [Related]
8. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
Pinto A; Naci H; Neez E; Mossialos E
Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
[TBL] [Abstract][Full Text] [Related]
9. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.
Lexchin J
BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254
[TBL] [Abstract][Full Text] [Related]
10. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
11. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
Lemieux J; Audet S
Curr Oncol; 2018 Jun; 25(Suppl 1):S161-S170. PubMed ID: 29910659
[TBL] [Abstract][Full Text] [Related]
12. Determinants of the Cancer Drug Funding Process in Canada.
Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
[TBL] [Abstract][Full Text] [Related]
13. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.
Chen AJ; Hu X; Conti RM; Jena AB; Goldman DP
Value Health; 2019 Dec; 22(12):1387-1395. PubMed ID: 31806195
[TBL] [Abstract][Full Text] [Related]
14. Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs.
Saluja R; Jiao T; Koshy L; Cheung M; Chan KKW
Curr Oncol; 2021 Jan; 28(1):606-618. PubMed ID: 33498460
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
Vivot A; Jacot J; Zeitoun JD; Ravaud P; Crequit P; Porcher R
Ann Oncol; 2017 May; 28(5):1111-1116. PubMed ID: 28453694
[TBL] [Abstract][Full Text] [Related]
16. The impact of cancer drug wastage on economic evaluations.
Truong J; Cheung MC; Mai H; Letargo J; Chambers A; Sabharwal M; Trudeau ME; Chan KKW
Cancer; 2017 Sep; 123(18):3583-3590. PubMed ID: 28640362
[TBL] [Abstract][Full Text] [Related]
17. Activities of the pan-Canadian Pharmaceutical Alliance: An Observational Analysis.
Rocchi A; Mills F
J Popul Ther Clin Pharmacol; 2018 Aug; 25(2):e12-e22. PubMed ID: 30725539
[TBL] [Abstract][Full Text] [Related]
18. Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs.
Becker DJ; Lin D; Lee S; Levy BP; Makarov DV; Gold HT; Sherman S
J Oncol Pract; 2017 Jul; 13(7):e653-e665. PubMed ID: 28493760
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
[TBL] [Abstract][Full Text] [Related]
20. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.
Srikanthan A; Mai H; Penner N; Amir E; Laupacis A; Sabharwal M; Chan KKW
Curr Oncol; 2017 Oct; 24(5):295-301. PubMed ID: 29089796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]